The TetraSens disposable eligible for reimbursement in South Korea
Pressrelease: Uppsala, on 4 March 2021. Senzime today announces that South Korea's state reimbursement system as of March 1[st] will compensate for the use of disposable sensors in general anesthesia using muscle relaxants in patients with ASA-PS 3 or higher.
There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used.
“This is a huge leap for patient safety and an acknowledgement of the need to monitor patients when muscle relaxants are used. South Korea is a forerunner in the race to minimize complications in this area and we follow the development in other countries closely”, says Pia Renaudin, CEO of Senzime.
The reimbursement of disposable sensors is an important stepstone in facilitating monitoring when neuromuscular blocking agents are used, and in line with other important initiatives like the European Society of Anesthesia and Intensive Care, ESAIC, task force working on Neuromuscular blockade management guidelines.
TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to South Korea, Senzime has launched sales of TetraGraph in Japan, Australia, Europe and the United States.
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org is Certified Adviser for Senzime. www.senzime.com